Those of us on Main St have a slight advantage over the guys on Wall St on this one. They have not noticed how fast this drug is being taken up and is truly a game changer in pain mgmt. Our hospital use is going up everyday. Every hospital in our area has on FL or is getting it soon. This is easily a $500 million/year drug which should equate to a conservative market cap of 2.5 billion (5x revs) in 2012. That is translates to a $40/share stock price. Wall St, thanks for giving me the opportunity to pick up more cheap shares.